Difference between revisions of "IPH-2101"
(Created page with "'''in clinical trials''' ==General information== Class/mechanism: Human monoclonal antibody that blocks the interaction of KIR inhibitory receptors on NK (natural killer) cells ...") |
m |
||
| Line 1: | Line 1: | ||
| − | |||
| − | |||
==General information== | ==General information== | ||
Class/mechanism: Human monoclonal antibody that blocks the interaction of KIR inhibitory receptors on NK (natural killer) cells with their ligands. It is hypothesized that by blocking these inhibitory signals, there will be enhanced activation of NK cells and tumor cell destruction.<ref>[http://www.innate-pharma.com/candidate/iph-2101 Innate Pharma's IPH 2101 (Anti-KIR) site]</ref><ref>[http://www.innate-pharma.com/mabs-targeting-nk-cells Information from Innate Pharma about monoclonal antibodies targeting NK cells]</ref> | Class/mechanism: Human monoclonal antibody that blocks the interaction of KIR inhibitory receptors on NK (natural killer) cells with their ligands. It is hypothesized that by blocking these inhibitory signals, there will be enhanced activation of NK cells and tumor cell destruction.<ref>[http://www.innate-pharma.com/candidate/iph-2101 Innate Pharma's IPH 2101 (Anti-KIR) site]</ref><ref>[http://www.innate-pharma.com/mabs-targeting-nk-cells Information from Innate Pharma about monoclonal antibodies targeting NK cells]</ref> | ||
| Line 13: | Line 11: | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Drug index]] | ||
| + | [[Category:Chemotherapy]] | ||
| + | [[Category:Intravenous chemotherapy]] | ||
| + | |||
| + | [[Category:Immunotherapy]] | ||
| + | [[Category:Antibody medications]] | ||
| + | [[Category:Anti-KIR medications]] | ||
| + | |||
| + | [[Category:Investigational]] | ||
Revision as of 03:27, 26 November 2014
General information
Class/mechanism: Human monoclonal antibody that blocks the interaction of KIR inhibitory receptors on NK (natural killer) cells with their ligands. It is hypothesized that by blocking these inhibitory signals, there will be enhanced activation of NK cells and tumor cell destruction.[1][2]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert.
Patient drug information
No information available.